FDA approves irinotecan liposome for first-line treatment of metastatic pancreatic adenocarcinoma
On February 13, 2024, the Food and Drug Administration approved irinotecan liposome (Onivyde, Ipsen Biopharmaceuticals, Inc.) with oxaliplatin, fluorouracil, and leucovorin, for the first-line treatment of metastatic pancreatic adenocarcinoma.
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: FDA Source Type: news
More News: Adenocarcinoma | Drugs & Pharmacology | Eloxatin | Food and Drug Administration (FDA) | Pancreas